Introduction Treatment-resistant depression (TRD) remains a major clinical challenge, with limited efficacy of available therapies. Psilocybin, a serotonergic psychedelic, has shown promising antidepressant effects. As recent studies have shown altered default mode network activity following psilocybin administration, further neuroimaging research in clinical populations is needed to clarify...
Esketamine has been shown to produce a major antidepressant response in patients with treatment-resistant depression (TRD). We evaluated the factors associated with achieving remission in these individuals. The study was carried out across four psychiatry departments in Madrid, Spain. Patients aged over 18 years were included if they received esketamine as an augmentation treatment for TRD....
We aim to provide an overview of the current state of knowledge about the efficacy of psilocybin in the treatment of depression, as well as its mechanisms of action. Psilocybin has a large, rapid, and persistent clinical effect in the treatment of resistant or end-of-life depression. Tolerance is good, with mild side effects limited to a few hours after dosing. The studies conducted to date...